What's new? Log in Free sign up

BioNTech SE (BNTX) News and press releases

Company Profile

News

From Benzinga Pro

Why BioNTech And Moderna Shares Are Falling After Pfizer News

BioNTech SE - ADR (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) shares are trading lower Tuesday morning in sympathy with Pfizer Inc. (NYSE:

Goldman Sachs Maintains Neutral on BioNTech, Lowers Price Target to $156

News, Price Target, Analyst Ratings

Goldman Sachs analyst Chris Shibutani maintains BioNTech (NASDAQ:BNTX) with a Neutral and lowers the price target from $177 to $156.

'U.K. Lawmakers Urge Pfizer Not To Raise The Price Of Its Covid-19 Vaccine' - Stat News

Biotech, News, General

https://www.statnews.com/pharmalot/2023/01/30/pfizer-covid19-vaccine-price-hike-uk/

$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns

Biotech, News, Education, Health Care, Small Cap, Top Stories, Trading Ideas, General

The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths.

Analyst Ratings for BioNTech

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on BioNTech, Raises Price Target to $216

News, Price Target, Analyst Ratings

Morgan Stanley analyst Matthew Harrison maintains BioNTech (NASDAQ:BNTX) with a Equal-Weight and raises the price target from $203 to $216.

COVID-19 Vaccine Strategy Might Follow The Influenza Shot Way, FDA To Decide Today

Biotech, Large Cap, News, Health Care, FDA, Top Stories, General

The FDA is considering a significant shift in the U.S.'s COVID-19 vaccine strategy to simplify vaccination against COVID-19.

FDA To Propose To Allow People To Get Latest Version Of Covid Vaccine Annually, Regardless of Boosters They Received

https://www.npr.org/sections/health-shots/2023/01/23/1150032238/fda-considers-major-shift-in-covid-vaccine-strategy

Google Layoffs 12K Employees, Netflix's Q4 Earnings And CEO Steps Down, FDA Rejects Eli Lilly's Alzheimer's Candidate: Top Stories Friday, Jan. 20

Biotech, Cryptocurrency, Earnings, Large Cap, News, Penny Stocks, Health Care, FDA, Top Stories, Markets, Movers, Tech, Media, Trading Ideas, General

Here's a round-up of stories from around the globe and from various media outlets. Benzinga

Israel Says No Stroke Risk Associated With Pfizer/BioNTech Updated COVID-19 Shots

Biotech, Large Cap, News, Health Care, Media, General

Israel health ministry official said Isreal had not identified any evidence linking strokes to an updated coronavirus vaccine by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX).

Shanghai Fosun Pharmaceutical Announced That Comirnaty Original/Omicron BA.4/BA.5 Bivalent Covid-19 Vaccine Is Officially Approved As A Regular Imported Vaccine By The Pharmaceutical Administration Bureau Of Macao SAR

On January 20, 2023, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

US Health Agencies Investigate Preliminary COVID-19 Vaccine Safety Signal In Older People

Biotech, Large Cap, News, Health Care, FDA, General

Chinese Officials Reported on Saturday 59,938 Covid Deaths In Hospitals Between December 8 And January 12, With Average Age Of 80.3 Years

https://www.reuters.com/world/china/china-reports-59938-covid-related-hospital-deaths-since-dec-8-2023-01-14/

'Chair Rodgers Statement On COVID-19 Vaccine Safety Signal'

Biotech, News, Politics, FDA, Legal, General

https://republicans-energycommerce.house.gov/posts/chair-rodgers-statement-on-covid-19-vaccine-reports House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) issued the following statement after

Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot

Biotech, Large Cap, News, Health Care, Small Cap, General

Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand.

BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British Startup

Biotech, M&A, News, Health Care, Movers, Tech, Trading Ideas, General

BioNTech to Acquire InstaDeep for £362M in Cash, Stock Plus Milestone Payments Up to £200M

BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML").

Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly

Biotech, Large Cap, News, Health Care, General

Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) reduced hospitalizations among older patients.

Israeli Study Shows Pfizer, Biontech Omicron COVID Booster Cuts Hospitalization in Over 65s

-Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/israeli-study-finds-omicron-covid-booster-cuts-hospitalization-65-2023-01-09/

Codexis Shares Up Following Reports China Is In Talks For Paxlovid Generic; Codexis In 2022 Announced Agreement With Pfizer To Supply Enzyme For The Manufacture Of Paxlovid

Biotech, News, Small Cap, General

https://www.codexis.com/investors/news-events/press-releases/detail/330/codexis-announces-agreement-with-pfizer-to-supply

Press releases

From Benzinga Pro

Non-small Cell Lung Cancer Clinical Trial 2023, Pipeline Drugs and Companies Insight Report: Analysis of Drugs, MOA, ROA, and Recent Developments by DelveInsight

News, Press Releases

"Non-small Cell Lung Cancer Pipeline"Non-small Cell Lung Cancer (NSCLC) pipeline constitutes 135+ key companies continuously working towards developing 150+ NSCLC treatment therapies, analyzes

BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development

Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging artificial intelligence and machine learning

BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030

Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech's footprint in the UKBioNTech aims to design and roll out randomized clinical

BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference

Mainz, Germany, December 28, 2022 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that CEO and Co-founder Prof. Ugur Sahin, M.D., will present a corporate overview and update at

BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate BNT165b1 expresses certain parts of the circumsporozoite protein (CSP)

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Approximately 11,500 of the companies' mRNA-based COVID-19 vaccine doses arrived on the Chinese Mainland to enable vaccination campaign for German expatriatesVaccines expected to be available in Beijing, Shanghai,

Update on First BioNTainer for African-based mRNA Manufacturing Facility

MAINZ, GERMANY, December 21, 2022 — BioNTech SE (NASDAQ:BNTX, "BioNTech")) reached the next milestone in the establishment of scalable mRNA vaccine production in Africa. The six ISO-sized shipping containers for the

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech's infectious disease mRNA vaccine collaboration with

Pfizer and BioNTech's Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

COMIRNATY Original & Omicron BA.4/BA.5 now authorized in Canada as a booster dose for children 5 through <12 years oldAuthorization is based on clinical, pre-clinical and manufacturing data for Omicron-adapted

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Bivalent vaccine authorized as third 3-µg dose in the three-dose primary seriesConsistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among children under 5 in

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected by BioNTech In

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to the companies'

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

NEW YORK and MAINZ, GERMANY, NOVEMBER 16, 2022 — Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) today announced that the companies have initiated a Phase 1 study to evaluate the safety, tolerability and

While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants

Small Cap, Opinion, Press Releases

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Nov. 16, 2022 /PRNewswire/ -- The COVID-19 pandemic has devastated the world and impacted millions of people… as a result, the demand for the creation of

Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

Small Cap, Opinion, Press Releases

FN Media Group Presents USA News Group News Commentary VANCOUVER, British Colombia, Nov. 14, 2022 /PRNewswire/ -- USA News Group - English actor, comedian and Monty Python alumnus Eric Idle credits early detection for

BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore

First mRNA manufacturing facility in Singapore will create regional manufacturing capacities in support of BioNTech's growing pipeline of mRNA-based vaccines and therapeutics across Asia Pacific region for both clinical

Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?

By Ernest Dela Aglanu, BenzingaMiami, FL--News Direct--Learn more about Organicell Regenerative Medicine, Inc.from this latest report.During the peak of the deadly COVID-19 pandemic, one novel therapeutic that seems to

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

NEW YORK and MAINZ, GERMANY, November 10, 2022 — Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY®

BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update

Earnings, Press Releases

BioNTech and Pfizer continue to build on global COVID-19 vaccine leadership with first-to-market Original/Omicron BA.4/BA.5-adapted bivalent vaccine launches across multiple countries and regions worldwide Approximately